Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD

Description

Skeletal muscle metabolic health is critical for mobility and an underrecognized target of metabolic acidosis in chronic kidney disease. Impaired muscle mitochondrial metabolism underlies poor physical endurance increasing the risk of mobility disability. The proposed project will use precise in vivo tools to study the pathophysiology of poor physical endurance in a clinical trial treating metabolic acidosis among persons living with chronic kidney disease.

Conditions

Chronic Kidney Diseases, Metabolic Acidosis, Fatigue, Physical Endurance, Insulin Resistance, Mitochondrial Energetics, Diabetes

Talk to us

Study Overview

On this page

Study Details

Study overview

Skeletal muscle metabolic health is critical for mobility and an underrecognized target of metabolic acidosis in chronic kidney disease. Impaired muscle mitochondrial metabolism underlies poor physical endurance increasing the risk of mobility disability. The proposed project will use precise in vivo tools to study the pathophysiology of poor physical endurance in a clinical trial treating metabolic acidosis among persons living with chronic kidney disease.

Randomized Cross-over Trial of Sodium Bicarbonate on Muscle Mitochondrial Energetics and Physical Endurance in Chronic Kidney Disease and Metabolic Acidosis

Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD

Condition
Chronic Kidney Diseases
Intervention / Treatment

-

Contacts and Locations

Sacramento

University of California Davis Health, Sacramento, California, United States, 95817

Nashville

Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Moderate-severe CKD determined by eGFR \<50ml/min per 1.73m2 by CKD EPI equation on at least 2 consecutive occasions.
  • * Metabolic acidosis defined as bicarbonate level\<24 on two consecutive occasions. Bicarbonate level of 24 or less allowed if eGFR\<=45ml/min per 1.73m2
  • * Age 21 to 85 years old
  • * Type 2 diabetes managed with insulin treatment
  • * Poorly controlled diabetes (HgbA1c\>10%)
  • * History of persistent hyperkalemia (K\>5.4)
  • * Chronic treatment with renal replacement therapy
  • * History of aortic dissection or severe valvular heart disease
  • * Exercise induced angina
  • * Uncontrolled cardiac dysrhythmia
  • * Oxygen dependent COPD
  • * Symptomatic claudication
  • * End stage liver disease
  • * Mobility disability defined as inability to walk without human assistance
  • * Dementia or psychosis
  • * Patients who cannot consent
  • * Active use of IV drugs
  • * Non-english speaking
  • * History of transplant
  • * Implants that prohibit MRI measurements or trauma involving metal fragments
  • * Pacemaker
  • * Expectation to start dialysis during the course of study.
  • * Any condition which in the judgement of the clinical investigator places the participant at risk from participation in the study.

Ages Eligible for Study

21 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Davis,

Baback Roshanravan, MD, PRINCIPAL_INVESTIGATOR, UC Davis

Jorge Gamboa, MD PhD, PRINCIPAL_INVESTIGATOR, Vanderbilt University

Study Record Dates

2026-07-30